A facile turn-on chemiluminescence probe for sensitive imaging on aminopeptidase N activity

Aminopeptidase N, as a target for drug discovery, shows remarkable relationship with many diseases, especially liver injury and cancer. Herein, we explored a chemiluminescence (CL) probe for sensing APN by tethering APN-specific substrate group to the ortho-acrylated phenoxy-dioxetane scaffold. In this manner, two CL probes (APN-CL and BAPN-CL) were designed with non-capped leucine and butoxy-carbonyl capped leucine as the protecting group to preserve the chemiexcitation energy. The uncovered leucine was demonstrated to be essential for detection of APN activity by comparing the CL intensity of two CL probes. Probe APN-CL was turned on upon APN cleavage, resulting in a high chemiluminescent emission, while the chemiexcitation energy of probe BAPN-CL was still restrained even with the high-level APN. The result was elucidated by molecular docking simulation in further. Probe APN-CL exhibited fast response and high sensitivity with a detection limit of 0.068 U/L, and an excellent specificity for the discrimination of APN from biological ions, small molecules and other proteases commonly found in living system. By virtue of good stability and cell viability, probe APN-CL imaged abnormal level of APN in tumor cells and tumor-bearing mice. Moreover, this probe APN-CL could be easily used to evaluate APN inhibitors and APN level in plasma samples from 20 patients. Overall, as a facile and cost-effective probe, APN-CL will be a promising alternative in the early diagnosis of pathologies and cost-effective screening on inhibitors.

A diketopyrrolopyrrole-based ratiometric fluorescent probe for endogenous leucine aminopeptidase detecting and imaging with specific phototoxicity in tumor cells

Leucine aminopeptidase (LAP) is a vital proteolytic enzyme, and its overexpression is often associated with many physiological diseases, such as liver dysfunction and breast cancer. Therefore, the accurate measurement of LAP concentrations in cells is critical for the diagnosis and prevention of related diseases. Herein, a new ratiometric fluorescent probe, DPP-Leu, based on diketopyrrolopyrrole (DPP) was designed and synthesized for LAP detection based on the specific enzymatic cleavage of the N-terminal leucine residue. The fluorescence intensity ratio of DPP-Leu (I₅₄₈/I₆₅₁) showed a remarkable change in the presence of LAP, with a limit of detection of 0.011 U L^-1, and DPP-Leu was successfully applied to detect LAP in fetal bovine serum (FBS) and artificial urine. Cell imaging experiments revealed that DPP-Leu could target mitochondria and distinguish tumor cells with high LAP content from normal cells. Importantly, benefiting from the structural transformation of DPP-Leu to the photosensitizer 4 under LAP catalysis, the probe could kill tumor cells under light irradiation without damaging normal cells.

In vivo imaging via a red-emitting fluorescent probe to diagnosing liver cancer or drug-induced liver disease

Leucine aminopeptidase (LAP) as an important proteolytic enzyme, has been mainly found in hepatobiliary cells, and overexpressed in hepatoma cells. Herein, a new highly selective red-emitting fluorescent probe (DCDHF-Ala) for LAP has been synthesized based on 2-dicyanomethyldiene-3-cyano-2, 5-dihydrofuran (DCDHF) as fluorophore, and alanine (Ala) as the detection group. More importantly, it's the first time to use Ala as a reactive group for LAP. DCDHF-Ala has a low detection limit (0.20 U/L), excellent water solubility and cell membrane permeability. In addition, the probe has been successfully applied to fluorescent imaging in cells and zebrafish. It's especially worth mentioning that, DCDHF-Ala has a high biosafety and enables a real-time detection of LAP levels in mice model. What's the most important is that DCDHF-Ala may be an effective tool to qualitatively monitor the upregulation of LAP induced by liver injury and liver cancer.

A ratiometric fluorescent probe based on quinoline for monitoring and imaging of Leucine aminopeptidase in liver tumor cells

Leucine aminopeptidase (LAP) is known as an important potential biomarker for liver malignancy and it is urgent to develop an intuitive and effective method to monitor the activity of LAP in liver cancer. Although, numerous LAP fluorescent probes had been developed, it is still a challenge to detect LAP activity in liver cancer. Herein, combained with the DFT, we reported a novel galactose-appended hepatoma-specific ratiometric fluorescent probe (Gal-QL-Leu) based on quinoline group for imaging and tracing LAP in liver tumor cells. Probe Gal-QL-Leu demonstrated a obvious ratiometric characteristics, better selectivity, good biocompatibility and high sensitivity. Moreover, the selective imaging of LAP in HepG2, HCT116, A549 and HeLa cells had been achieved with probe Gal-QL-Leu, demonstrating good application prospect in the detection of LAP activity in liver tumor cells.